MSI2 and acute lymphoblastic leukemia: In accordance with our results, limited data from other hematologic malignancies also identified high MSI2 expression as a negative prognostic marker in acute myeloid leukemia (Byers et al., 2011), acute lymphoblastic leukemia (Mu et al., 2013), chronic lymphocytic leukemia (Palacios et al., 2021), and aggressive mantle cell lymphoma (Sureda-Gómez et al., 2023).